Sanofi provides information on the adaptation of its activities in France through 2015

Paris, September 25, 2012 - Sanofi will communicate to its social partners in the coming days a project for the adaptation of its activities in France through 2015 before beginning information and consultation procedures in October.

This project would be a continuation of the three key strategic objectives presented on July 5th:

- Establish new momentum for success in our research activities which is necessary to ensure the Group's sustainability. Our R&D sites' activities in France would evolve over the next three years to strengthen our scientific, academic and private network.
  - The development activities in Vitry/Alfortville, Chilly-Mazarin/Longjumeau and Lyon would continue in their current configuration.
  - The Montpellier site would progressively evolve toward a strategic center focused on development.
  - The Vitry/Alfortville and Chilly-Mazarin/Longjumeau research activities would be increased.
  - The Strasbourg site would maintain its momentum of a collaborative platform open to academic research and biotechs.
  - A global center of excellence in infectious diseases would be created in Lyon.
- Improve the economic performance of Sanofi Pasteur's industrial units to ensure their ability to compete in increasingly competitive vaccine markets.
- Streamline support functions to respond to the Group's diversification and improve their efficiency.

Sanofi intends to implement these adaptations mainly through voluntary measures which could lead – by 2015 – to the reduction of approximately 900 positions in France. These measures would consist of early retirements, mobility proposals and repositioning in France. No relocation of sites or any change to the number of industrial sites is planned in France.

The function of the Toulouse site remains to be specified. Sanofi has identified during the summer potential stakeholders who could maintain the site's scientific or technological capacity. To further explore all options, a working group including Sanofi representatives, national and local authorities will be created as soon as possible. Its mission will be to find concrete solutions for the site in the coming months.

About Sanofi

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Forward Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group’s ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2011. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Contacts :

Media Relations
Jean-Marc Podvin
+ (33) 1 53 77 46 46
E-mail : mr@sanofi.com

Investor Relations
Sébastien Martel
+ (33) 1 53 77 45 45
E-mail : ir@sanofi.com